ELEVATE Early LEvosimendan Vs Usual Care in Advanced Chronic hearT failurE

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Niguarda Hospital
Sponsor:
Collaborator:
Orion Corporation, Orion Pharma
Information provided by (Responsible Party):
Niguarda Hospital
ClinicalTrials.gov Identifier:
NCT01290146
First received: February 3, 2011
Last updated: June 9, 2014
Last verified: June 2014

February 3, 2011
June 9, 2014
February 2011
March 2015   (final data collection date for primary outcome measure)
Number of days alive free of Transplant and out-of-hospital (DAOH) [ Time Frame: Measured at 12 months ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01290146 on ClinicalTrials.gov Archive Site
  • Incidence of acute renal dysfunction [ Time Frame: Measured at at 24 hours since inception of randomized treatment for acute worsening HF ] [ Designated as safety issue: Yes ]
    proportion of subjects who develop AKIN stage 1 (increase > 0.3 mg/dl or > 25% in serum creatinine from previous visit)
  • All cause mortality, hospital readmission and unscheduled office and emergency department visits for ADCHF [ Time Frame: Measured at 12 months ] [ Designated as safety issue: Yes ]
    A combination of all cause hospital admissions/death/urgent heart transplantation/LV assist device implantation
  • BNP changes [ Time Frame: Measured at at end-of- study and at each eventual destabilization ] [ Designated as safety issue: No ]
    Percent changes in BNP vs baseline
  • Number of hospital admissions for acute worsening HF [ Time Frame: Measured at 12 months ] [ Designated as safety issue: Yes ]
    Number of hospital admissions for acute worsening HF
  • Costs [ Time Frame: Measured at 12 months ] [ Designated as safety issue: No ]
    Direct health care costs for days in hospital, supplementary visits, drug treatment
  • Treatment-related adverse events [ Time Frame: Measured at 12 months ] [ Designated as safety issue: Yes ]
    death, hospital a dimission, emergency room or clinic unscheduled visits
  • Adverse changes in blood pressure or heart rate [ Time Frame: Measured at 24 hours after iv treatment ] [ Designated as safety issue: Yes ]
    Hypotension (< 90 mmHg), tachycardia (> 110 bpm)
  • ECG changes [ Time Frame: Measured at 24 hours after iv treatment ] [ Designated as safety issue: Yes ]
    Rhythm, rate, conduction disturbances, ventricular arrhythmias, repolarization changes
Same as current
Not Provided
Not Provided
 
ELEVATE Early LEvosimendan Vs Usual Care in Advanced Chronic hearT failurE
Early Use of Levosimendan Compared to Usual Care in Advanced Chronic Heart Failure (ACHF)

The purpose of this study is to compare in patients with Advanced Chronic Heart Failure the effects of Levosimendan versus diuretic (single 24-hour infusion) applied at the early detection of impending destabilization on hospitalization-free survival during 12 months.

Patients with advanced chronic heart failure (ACHF) have a short term reduced life expectancy with recurrent hospital admissions for clinical exacerbations. Levosimendan improves contractility by calcium-dependent binding to troponin C, determines vasodilation of the coronary arteries and systemic resistance vessels, thus decreasing preload and afterload, while exerting a protective effect on the myocardium against ischemia-reperfusion damage. In randomized clinical trials of acute heart failure patients, levosimendan improved hemodynamics and patients' quality of life and decreased natriuretic peptide plasma levels, with no excess mortality The study will assess whether the administration of levosimendan (single 24-hour infusion) at the early detection of deterioration may reduce frequency and duration of hospital admissions, improve functional status and quality of life in ACHF patients, with respect to diuretic infusion.

BACKGROUND Patients with advanced chronic heart failure (ACHF) have a short term reduced life expectancy with recurrent hospital admissions for clinical exacerbations. ACHF poses a heavy burden to cardiology departments, where these patients are referred for the severity of their clinical condition, which require a specialist approach, and results in high health care costs due to frequent rehospitalizations.

Patients with ACHF ≥ 2 hospital admissions in 6 months are at high risk of recurrent exacerbations. The benefits of strict outpatient follow-up at specialised HF vs standard community care in ACHF patients have been consistently demonstrated. The standard approach at HF clinics is based on flexible diuretic dose and outpatient iv diuretics as bolus or infusion at early signs of decompensation. Although this strategy results in symptomatic benefit and prevents approximately one third of hospital admission for acute exacerbations, a relevant proportion of patients will still need hospitalization. Predictors of lack of benefit are low systolic blood pressure, prior increase in oral diuretics and beta-blocker use, which taken together represent markers of severe disease susceptible to evolve in a low output state.

In the HF clinic setting, a novel strategy for these patients, to include early support to myocardial contractility, i.e. before compelling criteria for hospital admission become manifest, might prevent further prolonged hospitalizations, myocardial damage and impairment in renal function TRIAL RATIONALE Levosimendan improved hemodynamics and patients' quality of life and decreased natriuretic peptide plasma levels, with no excess mortality, in randomized clinical trials of acute heart failure. In SURVIVE an early larger treatment effect of levosimendan was apparent in patients with acute worsening of chronic HF treatment than in those with de novo disease, possibly because a greater proportion of these patients may be on beta-blockers, that are known to interfere with dobutamine or may potentiate the circulatory actions of levosimendan. Thus levosimendan may be unattractive first-line agent in destabilized ACHF patients on beta-blockers.

Based on the drug cardioprotective properties, hemodynamic and neurohormonal effects, we propose a novel therapeutic approach for the clinically-driven use of levosimendan in recurrent acute exacerbations of ACHF.

Dosing of the drug will omit the bolus to increase tolerability in this severely ill patient population.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Advanced Chronic Heart Failure
  • Drug: Diuretics
    Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
  • Drug: Levosimendan

    Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.

    Starting doses will be based on baseline SBP levels

    • SBP ≥ 85-99mmHg: 0.05 mcg/kg/min
    • SBP ≥100 mmHg: 0.1 mcg/kg/min
  • Active Comparator: Diuretics
    Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
    Intervention: Drug: Diuretics
  • Experimental: Levosimendan

    Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.

    Starting doses will be based on baseline SBP levels

    • SBP ≥ 85-99mmHg: 0.05 mcg/kg/min
    • SBP ≥100 mmHg: 0.1 mcg/kg/min
    Intervention: Drug: Levosimendan
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
134
May 2015
March 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Written informed consent
  • Systolic dysfunction (LVEF ≤ 35% by echo assessment within 6 months before enrolment)
  • No requirement for hospital admission for diagnostic work up or elective treatment to define etiology and/or treatment plan
  • Already on optimal standard HF treatment based on individual tolerance, including cardiac resynchronization therapy (CRT)/ICD device according to current guidelines
  • At least 2 hospital admissions for HF in the 6 months before enrolment, the most recent one within 30-90 days before enrolment with requirement for inotrope administration

Exclusion Criteria:

  • Participant in other studies in the last 30 days
  • Life expectancy < 1 year for comorbid conditions other than HF
  • Pregnancy, lactation, childbearing potential unless on adequate contraception
  • Acute coronary syndromes, percutaneous or surgical revascularization, valve surgery performed within 8 weeks before enrolment
  • Planned percutaneous or surgical procedures (except for heart transplantation)
  • CRT within 6 months before enrolment
  • Cardiogenic shock
  • Supine systolic BP < 85 mmHg
  • Severe liver insufficiency (>three-fold increase in AST-ALT )
  • Sever chronic kidney dysfunction (estimated GFR < 30 ml/min)
  • Sustained ventricular tachycardia
  • Severe chronic or current acute infection (temperature >38 C, WBC >15,000/mm3)
  • Severe chronic obstructive pulmonary disease (FEV1 <30% predicted or on oxygen therapy)
  • Severe persistent anemia (Hb < 10 g/l))
  • ACHF exacerbation due to conditions requiring specific treatment (e.g. anemia, atrial fibrillation, supraventricular tachycardia ) Documented low compliance or unavailable for programmed follow-up visits and phone contact
Both
18 Years to 80 Years
No
Contact: Renata De Maria, MD +39 02 6610 ext 1344 renata_de_maria@hotmail.com
Italy
 
NCT01290146
EudraCT code 2009-016958-41, FO002
No
Niguarda Hospital
Niguarda Hospital
Orion Corporation, Orion Pharma
Study Chair: Fabrizio Oliva, MD Heart Failure Heart Transplant Program, Cardiovascular Department, Niguarda Hospital, Milan, Italy
Study Chair: Michele Senni, MD Cardiovascular Medicine Ospedali Riuniti, Bergamo, Italy
Niguarda Hospital
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP